Article Text

Download PDFPDF

E-122 Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model
  1. S Manupipatpong1,
  2. A Pasciak1,
  3. F Hui2,
  4. R Krimins3,
  5. L Gainsburg4,
  6. M Dreher5,
  7. D Kraitchman6,
  8. C Weiss1
  1. 1Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD
  2. 2Neurointerventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD
  3. 3Anesthesiology and Critical Care Medicine; Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD
  4. 4Mid-Atlantic Veterinary Neurology and Neurosurgery, Catonsville, MD
  5. 5BTG/Boston Scientific, Oxford, CT
  6. 6Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD


Introduction/Purpose Glioblastoma multiforme is the most common and aggressive type of brain tumor, with a median survival time of 15 months despite treatment. We propose the use of Y-90 endovascular radiosurgery (ER) to increase treatment efficacy while reducing the neurotoxicity associated with radiotherapy in glioblastoma. To that end, this study aimed to evaluate the safety and feasibility of Y-90 ER in the treatment of glioma in a canine model.

Materials and Methods Three healthy research dogs (R1-3) and five client-owned dogs on anti-epileptics with spontaneous, intra-axial brain masses (P1-5) received unilateral Y-90 glass microsphere infusions in either the PCA (R1), MCA (R2), or ICA (R3, P1-5), followed by quantitative Y-90 PET/CT. R1-3 had neurological exams, as clinically indicated, and a 4-week post-ER MRI. P1-4 had serial neurological exams and 1-, 3-, and 6-month MRIs. Due to a small sample size, only descriptive statistics are reported.

Results R2-3 developed transient neurologic defects consistent with the treated side, which resolved in 13 days. R1 had no post-procedure neurologic deficits. The treated hemisphere in R1-3 received a maximum of 378±121Gy (x̄±σ) of radiation, with maximum dose twice as high in more distal deliveries (PCA, MCA). MRIs at 1 month were normal without atrophy or microinfarction.

All dogs except P2 were on corticosteroids and seizure-free prior to treatment. P1-3 had transient post-procedure neurologic deficits which resolved in 20–33 days, while P4 had no neurologic deficits. P5 passed away 12-hours post-ER. The masses received 46.2±11.7Gy of radiation with 19.3±12.2% of the mass volume receiving >70Gy. MRIs at 1-month post-ER showed decreased mass size in all four dogs: by 69% and 59% in P1 and P2 on post-contrast MRI and by 24% and 26% in P3 and P4 on FLAIR MRI. The average number of spheres per cm3 of lesion, calculated using the measured activity per cm3 on PET/CT and expected activity per bead, ranged from 1490 (P2) to 5280 (P1).

At 53 days, P2’s seizures returned with tumor enlargement, and he was euthanized 5 months post-ER. P1 remained asymptomatic until her 6-month visit, when left rear limb proprioceptive delay was observed. At her 12-month follow-up, left thoracic limb proprioceptive delay was also observed, though this did not suggest significant change in the known right cerebral cortex lesion. P3 remained asymptomatic with stable disease at his 6-month visit. P4 developed medically manageable seizure activity and a unilateral menace deficit with no mass growth on MRI at 3 months post-ER, though at 6 months mass volume began trending towards pre-treatment size.

Conclusion Y-90 ER in the canine brain is technically feasible and caused no permanent neurologic deficit despite >400Gy of radiation to critical brain structures. Four of five patient dogs had favorable dosimetric, radiologic, and clinical outcomes, all outliving the 63-day mean survival time associated with their original diagnosis and symptomatic treatment. Long-term outcomes, histopathology, and a larger sample size are needed to better understand brain Y-90 ER viability.

Disclosures S. Manupipatpong: None. A. Pasciak: None. F. Hui: None. R. Krimins: None. L. Gainsburg: None. M. Dreher: 5; C; BTG/Boston Scientific. D. Kraitchman: None. C. Weiss: 1; C; BTG/Boston Scientific. 2; C; BTG/Boston Scientific.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.